[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

4D Molecular Therapeutics Inc (FDMT)

4D Molecular Therapeutics Inc (FDMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 526,419
  • Shares Outstanding, K 52,276
  • Annual Sales, $ 85,210 K
  • Annual Income, $ -140,110 K
  • EBIT $ -180 M
  • EBITDA $ -180 M
  • 60-Month Beta 2.70
  • Price/Sales 6.37
  • Price/Cash Flow N/A
  • Price/Book 1.20

Options Overview Details

View History
  • Implied Volatility 141.37% (-13.15%)
  • Historical Volatility 75.59%
  • IV Percentile 29%
  • IV Rank 14.72%
  • IV High 545.35% on 01/08/26
  • IV Low 71.64% on 07/22/26
  • Expected Move (DTE 26) 0.00 (0.00%)
  • Put/Call Vol Ratio 34.00
  • Today's Volume 35
  • Volume Avg (30-Day) 145
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 5,166
  • Open Int (30-Day) 5,362
  • Expected Range 10.07 to 10.07

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.04
  • Number of Estimates 3
  • High Estimate $-1.01
  • Low Estimate $-1.07
  • Prior Year $-0.98
  • Growth Rate Est. (year over year) -6.12%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.90 +1.67%
on 07/24/26
14.00 -28.07%
on 06/30/26
-1.55 (-13.34%)
since 06/24/26
3-Month
8.07 +24.78%
on 05/19/26
14.00 -28.07%
on 06/30/26
+0.67 (+7.13%)
since 04/24/26
52-Week
4.27 +135.61%
on 07/29/25
14.00 -28.07%
on 06/30/26
+5.46 (+118.44%)
since 07/24/25

Most Recent Stories

More News
4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population

After a single intravitreal dose of 4D-150, visual acuity and anatomic control was maintained with consistent and durable treatment burden reduction through 2 years  4D-150 continues to be well tolerated...

FDMT : 10.07 (-2.99%)
4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...

FDMT : 10.07 (-2.99%)
4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists

EMERYVILLE, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...

FDMT : 10.07 (-2.99%)
4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital

EMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...

FDMT : 10.07 (-2.99%)
HTGC : 15.73 (+0.58%)
4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD

4FRONT-2 global enrollment completed approximately 4 months ahead of initial projections 4FRONT-2 over-enrolled (anticipated N>500), with final patient randomization expected in Q3 2026, reflecting...

FDMT : 10.07 (-2.99%)
Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker

ALAMEDA, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting...

FDMT : 10.07 (-2.99%)
VANI : 1.2800 (-7.91%)
4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...

FDMT : 10.07 (-2.99%)
4DMT to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics...

FDMT : 10.07 (-2.99%)
4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy

4D Molecular Therapeutics (NASDAQ:FDMT) executives said the company is seeing strong clinical trial momentum for its lead retinal gene therapy candidate, 4D-150, as it advances through late-stage development...

FDMT : 10.07 (-2.99%)
4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics...

FDMT : 10.07 (-2.99%)

Business Summary

4D Molecular Therapeutics Inc. is a clinical-stage gene therapy company which develops product candidates using its targeted and evolved adeno-associated viruses vectors. It offers a portfolio of gene therapy product candidates focusing on the ophthalmology, cardiology and pulmonology therapeutic areas....

See More

Key Turning Points

3rd Resistance Point 10.94
2nd Resistance Point 10.70
1st Resistance Point 10.39
Last Price 10.07
1st Support Level 9.83
2nd Support Level 9.59
3rd Support Level 9.27

See More

52-Week High 14.00
Fibonacci 61.8% 10.28
Last Price 10.07
Fibonacci 50% 9.14
Fibonacci 38.2% 7.99
52-Week Low 4.27

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.